Cargando…

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

BACKGROUND: Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since December 2020 in the United Kingdom. Real-world data have shown the vaccines to be highly effective against Covid-19 and related...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andrews, Nick, Tessier, Elise, Stowe, Julia, Gower, Charlotte, Kirsebom, Freja, Simmons, Ruth, Gallagher, Eileen, Thelwall, Simon, Groves, Natalie, Dabrera, Gavin, Myers, Richard, Campbell, Colin N.J., Amirthalingam, Gayatri, Edmunds, Matt, Zambon, Maria, Brown, Kevin, Hopkins, Susan, Chand, Meera, Ladhani, Shamez N., Ramsay, Mary, Lopez Bernal, Jamie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781262/ https://www.ncbi.nlm.nih.gov/pubmed/35021002 http://dx.doi.org/10.1056/NEJMoa2115481

Ejemplares similares

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
por: Lopez Bernal, Jamie, et al.
Publicado: (2021)

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
por: Andrews, Nick, et al.
Publicado: (2022)

Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021–March, 2022: a national, observational, test-negative, case-control study
por: Powell, Annabel A, et al.
Publicado: (2023)

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England
por: Møller Kirsebom, Freja Cordelia, et al.
Publicado: (2022)

COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England
por: Kirsebom, Freja C M, et al.
Publicado: (2022)

Monitoring the COVID-19 immunisation programme through a national immunisation Management system – England’s experience
por: Tessier, Elise, et al.
Publicado: (2023)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Risk of hospitalisation and death in children with SARS-CoV-2 delta (B.1.612.2) infection
por: Thelwall, Simon, et al.
Publicado: (2022)

Author Correction: Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
por: Amirthalingam, Gayatri, et al.
Publicado: (2022)

Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
por: Amirthalingam, Gayatri, et al.
Publicado: (2021)

Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
por: Andrews, Nick, et al.
Publicado: (2022)

Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study
por: Stowe, Julia, et al.
Publicado: (2022)

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England
por: Powell, Annabel A, et al.
Publicado: (2021)

Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages( )
por: Nyberg, Tommy, et al.
Publicado: (2022)

Representativeness of whole-genome sequencing approaches in England: the importance for understanding inequalities associated with SARS-CoV-2 infection
por: Twohig, Katherine A., et al.
Publicado: (2023)

Seroprevalence of SARS-CoV-2 antibodies in university students: Cross-sectional study, December 2020, England
por: Vusirikala, Amoolya, et al.
Publicado: (2021)

Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England
por: Kirsebom, Freja Cordelia Møller, et al.
Publicado: (2022)

Impact of Extending the Timing of Maternal Pertussis Vaccination on Hospitalized Infant Pertussis in England, 2014–2018
por: Tessier, Elise, et al.
Publicado: (2020)

Real-world data on immune responses following heterologous prime-boost COVID-19 vaccination schedule with Pfizer and AstraZeneca vaccines in England
por: Westrop, Samantha J, et al.
Publicado: (2022)

Effectiveness of BNT162b2 and ChAdOx-1 vaccines in residents of long-term care facilities in England using a time-varying proportional hazards model
por: Paranthaman, Karthik, et al.
Publicado: (2022)

Descriptive epidemiology of SARS‐CoV‐2 Beta (B.1.351) variant cases in England, December 2020 to June 2022
por: Sinnathamby, Mary A., et al.
Publicado: (2023)

High attack rate in a large care home outbreak of SARS-CoV-2 BA.2.86, East of England, August 2023
por: Reeve, Lucy, et al.
Publicado: (2023)

Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England
por: Harman, Katie, et al.
Publicado: (2023)

SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England
por: Ismail, Sharif A, et al.
Publicado: (2021)

The changing epidemiology of diphtheria in the United Kingdom, 2009 to 2017
por: Gower, Charlotte M, et al.
Publicado: (2020)

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England
por: Mensah, Anna A, et al.
Publicado: (2022)

Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020
por: Jeffery-Smith, Anna, et al.
Publicado: (2021)

Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design
por: Stowe, Julia, et al.
Publicado: (2021)

Short-term changes in the health state of children with group B meningococcal disease: A prospective, national cohort study
por: Kennedy, Iain T. R., et al.
Publicado: (2017)

Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England()
por: Field, Nigel, et al.
Publicado: (2014)

Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021
por: Ireland, Georgina, et al.
Publicado: (2022)

Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England
por: Webster, H. H., et al.
Publicado: (2022)

Invasive meningococcal disease in England: assessing disease burden through linkage of multiple national data sources
por: Ladhani, Shamez N, et al.
Publicado: (2015)

Impact of the herpes zoster vaccination programme on hospitalised and general practice consulted herpes zoster in the 5 years after its introduction in England: a population-based study
por: Andrews, Nick, et al.
Publicado: (2020)

Crossing the Rubicon: A fine line between waiting and vaccinating adolescents against COVID-19
por: Ladhani, Shamez N
Publicado: (2021)

Face masking for children - time to reconsider
por: Ladhani, Shamez N
Publicado: (2022)

COVID-19 vaccination for children aged 5–11 years
por: Ladhani, Shamez N
Publicado: (2022)

Rapid molecular diagnostic tests fail to PERFORM in febrile children
por: Ladhani, Shamez N.
Publicado: (2023)

Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to BA.2 cases in England
por: Abdul Aziz, Nurin, et al.
Publicado: (2023)

Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021
por: Subbarao, Sathyavani, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hc1n4ip9tqj95gnoj5m0n1hsr7